<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176668</url>
  </required_header>
  <id_info>
    <org_study_id>YH4808-111</org_study_id>
    <nct_id>NCT02176668</nct_id>
  </id_info>
  <brief_title>The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Partial Crossover Study to Explore the Pharmacokinetics and the Pharmacodynamics of YH4808 New Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to explore pharmacodynamics and pharmacokinetics of
      YH4808 New Formulation in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Cmax of YH4808</measure>
    <time_frame>Day 1(Day 35), Day 7(Day 41)</time_frame>
    <description>Day 1(Day 35); predose, 11 times after dosing, Day 7(Day 41); predose, 13 times after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUC0-24h of YH4808</measure>
    <time_frame>Day 1(Day 35), Day 7(Day 41)</time_frame>
    <description>Day 1(Day 35); predose, 11 times after dosing, Day 7(Day 41); predose, 13 times after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUC0-24h of M3</measure>
    <time_frame>Day 1(Day 35), Day 7(Day 41)</time_frame>
    <description>Day 1(Day 35); predose, 11 times after dosing, Day 7(Day 41); predose, 13 times after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Cmax of M3</measure>
    <time_frame>Day 1(Day 35), Day 7(Day 41)</time_frame>
    <description>Day 1(Day 35); predose, 11 times after dosing, Day 7(Day 41); predose, 13 times after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the arithmetic mean of 24h intragastric pH monitoring</measure>
    <time_frame>Day 1(Day7)~Day2(Day8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the median of 24h intragastric pH monitoring</measure>
    <time_frame>Day 1(Day7)~Day2(Day8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration of stomach maintained over pH4 or 5</measure>
    <time_frame>Day 1(Day7)~Day2(Day8)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH4808 NF 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808 New Formulation 100mg after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 OF 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 NF 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 NF 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808 New Formulation 400mg after meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 NF 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808 New Formulation 100mg before meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 OF 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg before meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 NF 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 NF 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days repeat administration of YH4808 New Formulation 400mg before meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 NF 100</intervention_name>
    <description>The number of times : multiple-dose Rout : oral administration</description>
    <arm_group_label>YH4808 NF 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 OF 200</intervention_name>
    <description>The number of times : multiple-dose Rout : oral administration</description>
    <arm_group_label>YH4808 OF 200</arm_group_label>
    <arm_group_label>YH4808 NF 200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 NF 200</intervention_name>
    <description>The number of times : multiple-dose Rout : oral administration</description>
    <arm_group_label>YH4808 OF 200</arm_group_label>
    <arm_group_label>YH4808 NF 200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 NF 400</intervention_name>
    <description>The number of times : multiple-dose Rout : oral administration</description>
    <arm_group_label>YH4808 NF 400</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy adult age 20 to 55 over 55kg with ideal body weight(BMI) 18.5 ~ 25

          2. Subject who has no congenital, chronic disease and disease symptoms in medical
             examination result

          3. negative to Helicobacter pylori in 13C urea breath test

          4. Subject who judged to be eligible according to various test results including
             laboratory test(serum test, hematologic/blood chemistry examination, urine test, etc.)
             and 12-lead ECG test performed within 4 weeks before the first IP administration.

          5. Subject who agreed to maintain contraception and comply with medically verified
             contraception methods (including infertility)

        Exclusion Criteria:

          1. Subject who has history or presence of clinically significant disease in liver,
             kidney, nervous system, respiratory system, endocrine system, blood tumor,
             cardiovascular, reproductive, musculoskeletal system, mental disorder, ophthalmologic
             disease, and skin disease in investigator's judgement.

          2. Subject who has history of surgical operation or disease related to gastrointestinal
             symptoms (e.g. crohn's diseas, ulcer, etc. except for appendectomy or simple hernia)
             which could have influence on the absorption of IP.

          3. Subject who is hypersensitive to components contained in YH4808 and other
             drugs(aspirin, antibiotics, etc.)

          4. pregnant or lactating woman.

          5. Other exclusions apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min soo Park, Ph.D, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei Medical Center Severance Hospital Clinical Trials Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Medical Center Severance Hospital Clinical Trials Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

